<p>Fudan-Zhangjiang (01349.HK) announced its performance preliminary report for the fiscal year 2025, achieving revenue of 686 million RMB, a year-on-year decrease of 3.3%. The net loss attributable to shareholders was 157 million RMB, compared to a net profit of 39.73 million RMB in the previous year, turning from profit to loss; the loss per share was 0.15 RMB</p>

588130

688505

159837

512290

159992

512010

516930

516500

510660

159849

<p>Fudan-Zhangjiang announced its performance report for the year 2025, achieving revenue of 686 million RMB (same below), a year-on-year decrease of 3.3%. The net loss attributable to shareholders was 157 million RMB, compared to a net profit of 39.73 million RMB in the previous year, turning from profit to loss; the loss per share was 0.15 RMB</p>

AASTOCKS

ChinaAMC SSE STAR Biology and Medicine ETF

Fudan-Zhangjiang

E Fund CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Merchants CSI Biotechnology Theme ETF

"Performance" Fudan-Zhangjiang reported a full-year loss of 157 million RMB, turning from profit to loss